SG10202007834VA - Compositions and methods of manufacturing protein microparticles - Google Patents
Compositions and methods of manufacturing protein microparticlesInfo
- Publication number
- SG10202007834VA SG10202007834VA SG10202007834VA SG10202007834VA SG10202007834VA SG 10202007834V A SG10202007834V A SG 10202007834VA SG 10202007834V A SG10202007834V A SG 10202007834VA SG 10202007834V A SG10202007834V A SG 10202007834VA SG 10202007834V A SG10202007834V A SG 10202007834VA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- protein microparticles
- manufacturing protein
- manufacturing
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000011859 microparticle Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562268259P | 2015-12-16 | 2015-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202007834VA true SG10202007834VA (en) | 2020-09-29 |
Family
ID=57708873
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202007834VA SG10202007834VA (en) | 2015-12-16 | 2016-12-16 | Compositions and methods of manufacturing protein microparticles |
SG11201803197UA SG11201803197UA (en) | 2015-12-16 | 2016-12-16 | Compositions and methods of manufacturing protein microparticles |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803197UA SG11201803197UA (en) | 2015-12-16 | 2016-12-16 | Compositions and methods of manufacturing protein microparticles |
Country Status (22)
Country | Link |
---|---|
US (1) | US20200022917A1 (en) |
EP (2) | EP3389636B1 (en) |
JP (2) | JP7185526B2 (en) |
KR (1) | KR20180088836A (en) |
CN (2) | CN114404371A (en) |
AU (2) | AU2016369557B2 (en) |
BR (1) | BR112018010743B1 (en) |
CA (1) | CA3003654A1 (en) |
CL (2) | CL2018001623A1 (en) |
CO (1) | CO2018005920A2 (en) |
DK (1) | DK3389636T3 (en) |
EA (2) | EA201891164A1 (en) |
ES (1) | ES2927348T3 (en) |
HK (1) | HK1251461A1 (en) |
HU (1) | HUE060148T2 (en) |
IL (3) | IL302211A (en) |
MX (1) | MX2018005384A (en) |
PH (2) | PH12018500830A1 (en) |
PL (1) | PL3389636T3 (en) |
SG (2) | SG10202007834VA (en) |
WO (1) | WO2017106716A1 (en) |
ZA (1) | ZA201802706B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2790681B9 (en) | 2011-11-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying |
EA202090515A1 (en) * | 2017-08-18 | 2020-05-26 | Ридженерон Фармасьютикалз, Инк. | CAPILLARY IZOELECTRIC FOCUSING WITH DETECTION DIRECTLY IN CAPILLARY FOR ANALYSIS OF PROTEIN OPTIONS IN THE SAMPLE MATRIX |
GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
AU2020214626A1 (en) | 2019-01-31 | 2021-09-16 | Elektrofi, Inc. | Particle formation and morphology |
AU2020344675A1 (en) | 2019-09-13 | 2022-03-31 | Elektrofi, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
US20220411482A1 (en) * | 2019-11-15 | 2022-12-29 | Silk Technologies, Ltd. | Stable formulations of silk-derived protein |
KR20220104797A (en) * | 2019-11-25 | 2022-07-26 | 리제너론 파마슈티칼스 인코포레이티드 | Sustained release formulation using non-aqueous emulsion |
US20230094393A1 (en) * | 2020-02-07 | 2023-03-30 | Elektrofi, Inc. | Peptide particles and methods of formation |
KR20230113280A (en) * | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | Sustained release formulation using non-aqueous membrane emulsification method |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4210529A (en) | 1974-12-26 | 1980-07-01 | Midwest Research Institute | Blood compatible polymers and applications thereof |
US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
US4764364A (en) | 1986-02-25 | 1988-08-16 | S R I International | Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product |
US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
US5104221A (en) | 1989-03-03 | 1992-04-14 | Coulter Electronics Of New England, Inc. | Particle size analysis utilizing polarization intensity differential scattering |
ATE194384T1 (en) | 1989-09-12 | 2000-07-15 | Hoffmann La Roche | TNF-BINDING PROTEINS |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5968543A (en) | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
EP0913177A1 (en) * | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Process for producing dry, amorphous products comprising biological active materials by means of convection drying technique, especially spray drying |
US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
SG106672A1 (en) | 2002-03-08 | 2004-10-29 | Asml Netherlands Bv | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
DE10339197A1 (en) * | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried amorphous powder with low residual moisture and good storage stability |
JP4627425B2 (en) | 2004-09-29 | 2011-02-09 | 本田技研工業株式会社 | Shift control device for continuously variable transmission |
AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
CN101613409B (en) | 2005-06-17 | 2014-06-04 | 英克隆有限责任公司 | PDGFR-alpha antibody |
WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
LT2944306T (en) * | 2006-06-16 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
CA2682390A1 (en) | 2007-04-17 | 2008-10-30 | Imclone Llc | Pdgfr.beta.-specific inhibitors |
MX2010007728A (en) * | 2008-01-15 | 2010-12-21 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same. |
DK2274008T3 (en) | 2008-03-27 | 2014-05-12 | Zymogenetics Inc | Compositions and Methods for Inhibition of PDGFRBETA and VEGF-A |
JP2012520311A (en) * | 2009-03-11 | 2012-09-06 | プレキシコン インコーポレーテッド | Pyrrolo [2,3-B] pyridine derivatives for inhibition of RAF kinase |
JO3182B1 (en) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | High Affinity Human Antibodies to Human Angiopoietin-2 |
AU2011274363A1 (en) | 2010-07-02 | 2013-01-24 | Medimmune, Llc | Antibody formulations |
JOP20190250A1 (en) * | 2010-07-14 | 2017-06-16 | Regeneron Pharma | Stabilized formulations containing anti-ngf antibodies |
AR087305A1 (en) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT |
EP2790681B9 (en) * | 2011-11-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying |
BR112014028600B1 (en) | 2012-05-18 | 2022-11-22 | Genentech, Inc | SUSPENSION FORMULATIONS COMPRISING HIGH CONCENTRATION MONOCLONAL ANTIBODY, ITS METHOD OF PREPARATION, ITS USE AND DEVICE FOR SUBCUTANEOUS ADMINISTRATION, AND METHOD FOR PRODUCING AN ARTICLE OF MANUFACTURING |
JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
-
2016
- 2016-12-16 CN CN202210095360.9A patent/CN114404371A/en active Pending
- 2016-12-16 EP EP16820541.7A patent/EP3389636B1/en active Active
- 2016-12-16 DK DK16820541.7T patent/DK3389636T3/en active
- 2016-12-16 IL IL302211A patent/IL302211A/en unknown
- 2016-12-16 KR KR1020187016572A patent/KR20180088836A/en not_active Application Discontinuation
- 2016-12-16 IL IL286601A patent/IL286601B2/en unknown
- 2016-12-16 JP JP2018531166A patent/JP7185526B2/en active Active
- 2016-12-16 CA CA3003654A patent/CA3003654A1/en active Pending
- 2016-12-16 ES ES16820541T patent/ES2927348T3/en active Active
- 2016-12-16 WO PCT/US2016/067280 patent/WO2017106716A1/en active Application Filing
- 2016-12-16 EA EA201891164A patent/EA201891164A1/en unknown
- 2016-12-16 CN CN201680072951.7A patent/CN108366968B/en active Active
- 2016-12-16 EP EP22172044.4A patent/EP4059492B1/en active Active
- 2016-12-16 AU AU2016369557A patent/AU2016369557B2/en active Active
- 2016-12-16 EA EA202192290A patent/EA202192290A1/en unknown
- 2016-12-16 PL PL16820541.7T patent/PL3389636T3/en unknown
- 2016-12-16 HU HUE16820541A patent/HUE060148T2/en unknown
- 2016-12-16 SG SG10202007834VA patent/SG10202007834VA/en unknown
- 2016-12-16 US US15/775,479 patent/US20200022917A1/en active Pending
- 2016-12-16 SG SG11201803197UA patent/SG11201803197UA/en unknown
- 2016-12-16 MX MX2018005384A patent/MX2018005384A/en unknown
- 2016-12-16 BR BR112018010743-3A patent/BR112018010743B1/en active IP Right Grant
-
2018
- 2018-04-18 PH PH12018500830A patent/PH12018500830A1/en unknown
- 2018-04-23 ZA ZA2018/02706A patent/ZA201802706B/en unknown
- 2018-05-08 IL IL259204A patent/IL259204B/en unknown
- 2018-06-08 CO CONC2018/0005920A patent/CO2018005920A2/en unknown
- 2018-06-15 CL CL2018001623A patent/CL2018001623A1/en unknown
- 2018-08-23 HK HK18110907.1A patent/HK1251461A1/en unknown
-
2021
- 2021-03-17 PH PH12021550603A patent/PH12021550603A1/en unknown
-
2022
- 2022-09-30 JP JP2022157741A patent/JP2022185057A/en active Pending
- 2022-12-22 AU AU2022291549A patent/AU2022291549A1/en active Pending
-
2023
- 2023-08-09 CL CL2023002345A patent/CL2023002345A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252870A1 (en) | Sirp polypeptide compositions and methods of use | |
IL286601B1 (en) | Compositions and methods of manufacturing protein microparticles | |
HK1252757A1 (en) | Compositions and methods for degradation of misfolded proteins | |
GB201502086D0 (en) | Methods of manufacturing and cleaning | |
GB201513304D0 (en) | Compositions and Methods | |
ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
HK1254960A1 (en) | Cryoprecipitate compositions and methods of preparation thereof | |
HK1251979A1 (en) | Peptide compositions and methods of use | |
HK1254028A1 (en) | Anti-malaria compositions and methods | |
HK1250345A1 (en) | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same | |
HK1252057A1 (en) | Novel method of use and compositions | |
HK1247136A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
GB2544343B (en) | Receptacle and its method of manufacture | |
GB201607910D0 (en) | Microparticles and composition | |
SG11201705490QA (en) | Mercaptanized vinylnorbornene compositions and methods of making same | |
GB201509023D0 (en) | Compositions and methods of production thereof | |
GB201512996D0 (en) | Compositions and methods | |
PL3445730T3 (en) | Stone-glass macrocomposites and compositions and methods of making | |
IL242952A0 (en) | Photodetector-arrays and methods of fabrication thereof | |
GB201514413D0 (en) | Compositions and methods | |
GB201509272D0 (en) | Microparticles and composition | |
GB201518638D0 (en) | Implants and methods of manufacturing implants | |
GB201510576D0 (en) | Implants and methods of forming thereof |